New Releases from NCBI BookshelfPembrolizumab (Keytruda): In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].​Pembrolizumab (Keytruda): In combination with fluoropyrimidine and platinum–containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].